Dr. Reich is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
202 Stratford Park Cir
Del Mar, CA 92014Phone+1 858-755-1732
Education & Training
- Boston University Medical CenterResidency, Internal Medicine, 1971 - 1973
- Rutgers New Jersey Medical SchoolClass of 1971
Certifications & Licensure
- MA State Medical License 1979 - 2021
Clinical Trials
- Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma Start of enrollment: 2006 May 01
- Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Start of enrollment: 2007 Mar 01
- Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies Start of enrollment: 2007 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 24 citationsMarizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data.Daniela A. Bota, Warren P. Mason, Santosh Kesari, Rajiv Magge, Benjamin Winograd
Neuro-Oncology Advances. 2021-01-01 - 54 citationsA phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results.Andrew Spencer, Simon J. Harrison, Jeffrey A. Zonder, Ashraf Z. Badros, Jacob P. Laubach
British Journal of Haematology. 2018-01-01 - 30 citationsFirst-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumorsGeoffrey I. Shapiro, Ulka N. Vaishampayan, Patricia LoRusso, Jeremy Barton, Steven Y. Hua
Investigational New Drugs. 2017-01-09
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: